News Focus
News Focus
icon url

Hoskuld

12/27/23 6:37 PM

#444410 RE: Joseph_K #444404

Thanks, good post. I take issue with your certainty regarding trial failure primarily because the company said it hit all its endpoints and has access to all the data and analysis and is on the record as saying it hit all the endpoints and the EMA apparently agrees...whereas (this is not meant to be mean) you have not seen the SAP nor seen the data and analysis. Could you be right? I have a STEM degree so I would say yes, but the chances that you are right are very, very slim. If you are right then you should line up as lead plaintiff in a class action because you would deserve to get a larger share than others.
icon url

XenaLives

12/27/23 8:45 PM

#444425 RE: Joseph_K #444404

The approval process .. and alleged "sliding scale" are farcical.:

This allows pharma to sell toxic drugs like flouroquinolones.

It's a cheat sheet.

AVXL and Blarcamesine don't need this.